Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy

被引：0
|
作者：
Heidy Cedeño
Rafael Araúz
Fernando Cebamanos
Idalmis de Torraza
Ana Porcell
机构：
[1] Instituto Oncológico Nacional,Department Internal Medicine
[2] Instituto Oncológico Nacional,Department of Medical Oncology
[3] Department of Radiation Oncology Instituto Oncológico Nacional,Department of Pathology
[4] Instituto Oncológico Nacional,undefined
来源：
BMC Cancer | / 7卷 / Suppl 1期
关键词：
Trastuzumab; Axillary Lymph Node; Anthracyclines; Advanced Breast Cancer; Complete Pathological Response;
D O I：
10.1186/1471-2407-7-S1-A50
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] HER-2/neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer
    Tulbah, AM
    Ibrahim, EM
    Ezzat, AA
    Ajarim, DS
    Rahal, MM
    El Weshi, AN
    Sorbris, R
    MEDICAL ONCOLOGY, 2002, 19 (01) : 15 - 23
  • [22] Her2/neu status in locally advanced breast cancer.
    Doran, CM
    Cameron, DA
    Watters, AD
    Leonard, RCF
    Bartlett, JMS
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 278 - 278
  • [23] Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy
    Stjepanovic, Neda
    Kumar, Sudhir
    Jerzak, Katarzyna J.
    Trudeau, Maureen
    Warner, Ellen
    Cao, Xingshan
    Eisen, Andrea
    Tran, William
    Pezo, Rossanna C.
    CLINICAL BREAST CANCER, 2024, 24 (08) : e723 - e730
  • [24] Pathological complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER2 amplification in locally advanced breast cancer.
    Arnould, L.
    Gelly-Marty, M.
    Couturier, J.
    Ferrant, E.
    Callier, P.
    Ettore, F.
    Sagan, C.
    Antoine, M.
    Penault-Llorca, F.
    Fumoleau, P.
    Coudert, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S49 - S49
  • [25] Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer
    Kogawa, T.
    Fouad, T.
    Liu, D.
    Shen, Y.
    Masuda, H.
    Mac Gregor, M. Chavez
    Alvarez, R.
    Valero, V.
    Hortobagyi, G.
    Ueno, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S418 - S419
  • [26] Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer
    Li, Peifeng
    Liu, Tantan
    Wang, Yingmei
    Shao, Shuai
    Zhang, Weichen
    Lv, Yang
    Yi, Jun
    Wang, Zhe
    CLINICAL BREAST CANCER, 2013, 13 (01) : 53 - 60
  • [27] Can mammographic breast density predict complete pathological response in patients with locally advanced breast cancer following neoadjuvant chemotherapy?
    Agarwal, Veenoo
    Spalding, Lisa
    Blick, Tony
    Thompson, Erik W.
    Dobrovic, Alexander
    Redfern, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 65 - 65
  • [28] Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
    Huyen Thi Phung
    Hoa Thi Nguyen
    Tung Van Nguyen
    Tai Van Nguyen
    Lan Anh Thi Dinh
    Chu Van Nguyen
    BREAST CANCER-TARGETS AND THERAPY, 2020, 12 : 117 - 122
  • [29] Studies on factors for pathological complete response after neoadjuvant chemotherapy in relation to HER2 status in primary breast cancer
    Arima, Nobuyuki
    Nishimura, Reiki
    Muramoto, Kazuhiro
    Inayoshi, Atsushi
    Tanigawa, Tomio
    Watanabe, Sugiko
    CANCER RESEARCH, 2024, 84 (09)
  • [30] PREDICTABILITY OF POST-NEOADJUVANT CHEMOTHERAPY MRI FOR PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE AND HER2 POSITIVE BREAST CANCERS
    Ben-Zvi, Libby
    Martinez, Constanza
    Meterissian, Sarkis
    Lambert, Christine
    Hijal, Tarek
    RADIOTHERAPY AND ONCOLOGY, 2022, 174 : S40 - S40
12345